Trial Profile
A retrospective study to evaluate long term response to Vemurafenib in patients with metastatic melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2017
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 13 Jun 2017 New trial record
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.